Faga Daniel

President, CEO, DirectorFirst Tracks Biotherapeutics, Inc. (TRAX) · full profile →Form 4 · filed Apr 22, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
11
0 non-derivative · 11 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 20, 2026Grant(A)11K$011K
Apr 20, 2026Grant(A)2K$02K
Apr 20, 2026Grant(A)9K$09K
Apr 20, 2026Grant(A)195K$0195K
Apr 20, 2026Grant(A)380K$0380K
Apr 20, 2026Grant(A)306K$0306K
Apr 20, 2026Grant(A)133K$0133K
Apr 20, 2026Grant(A)18K$018K
Apr 20, 2026Grant(A)69K$069K
Apr 20, 2026Grant(A)81K$081K
Apr 20, 2026Grant(A)99K$099K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001673528-26-000010) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.